<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02714283</url>
  </required_header>
  <id_info>
    <org_study_id>CER-1503-29191</org_study_id>
    <nct_id>NCT02714283</nct_id>
  </id_info>
  <brief_title>Comparative Effectiveness and Safety of Inhaled Corticosteroids and Antimicrobial Compounds for Non-CF Bronchiectasis</brief_title>
  <official_title>Comparative Effectiveness and Safety of Inhaled Corticosteroids and Antimicrobial Compounds for Non-CF Bronchiectasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oregon Health and Science University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Patient-Centered Outcomes Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Jewish Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>COPD Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Oregon Health and Science University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to provide patients and their physicians with greater
      understanding of the risks and benefits of commonly used therapies for treatment of non-CF
      bronchiectasis
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Non-CF bronchiectasis is a chronic inflammatory lung disease that is closely linked to
      pulmonary NTM disease. Both are rare but rising in incidence and disproportionately affect
      the elderly and women. Therapy of non-CF bronchiectasis aims to reduce inflammation via
      either ICS-induced immunosuppression or antibiotic-associated immunomodulation and/or
      suppression of pathogenic organisms. Both strategies, pursued long-term alone or some cases
      concomitantly, have inherent risks, and the relative risks and benefits of these differential
      approaches are poorly studied to date. Ultimately, our study will provide patients and their
      physicians with greater understanding of the risks and benefits of these therapeutic choices.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 28, 2016</start_date>
  <completion_date type="Actual">July 1, 2018</completion_date>
  <primary_completion_date type="Actual">June 30, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Nontuberculous Mycobacterial (NTM) Disease</measure>
    <time_frame>up to 8 years</time_frame>
    <description>Incidence of treated pulmonary nontuberculous mycobacterium (NTM) disease</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hospitalized Respiratory Infection</measure>
    <time_frame>up to 8 years</time_frame>
    <description>Among a national cohort of non-CF bronchiectasis patients, we will compare the effectiveness of corticosteroid and macrolide therapy with regards to prevention of hospitalized respiratory infection.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sudden Cardiac Arrest</measure>
    <time_frame>up to 8 years</time_frame>
    <description>Myocardial infarction event</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sensorineural Hearing Loss</measure>
    <time_frame>up to 8 years</time_frame>
    <description>Sensorineural hearing loss.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hip Fracture</measure>
    <time_frame>up to 8 years</time_frame>
    <description>Hip fracture.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Opportunistic Infections</measure>
    <time_frame>up to 8 years</time_frame>
    <description>Opportunistic infections.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause Mortality</measure>
    <time_frame>up to 8 years</time_frame>
    <description>All-cause mortality.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause Hospitalization</measure>
    <time_frame>up to 8 years</time_frame>
    <description>All-cause hospitalization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemoptysis</measure>
    <time_frame>up to 8 years</time_frame>
    <description>Hemoptysis event</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arrhythmia</measure>
    <time_frame>up to 8 years</time_frame>
    <description>Arrhythmia (principal diagnosis)</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">90089</enrollment>
  <condition>Bronchiectasis</condition>
  <arm_group>
    <arm_group_label>Non-CF bronchiectasis patients</arm_group_label>
    <description>Complete national 2006-2014 Medicare data from Part A, B and D will be obtained from CMS. We will use bronchiectasis ICD-9 codes 494.0 and 494.1 to identify patients with bronchiectasis within Medicare. From this identified bronchiectasis cohort, we will exclude patients with cystic fibrosis (ICD-9 codes 277.00-277.09), HIV infection (042), and a history of organ transplant (V42.0, V42.1, V42.6, V42.7, V42.8).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>inhaled corticosteroid therapy</intervention_name>
    <description>We will evaluate and compare the clinical effectiveness and safety of long-term inhaled corticosteroid and macrolide antimicrobial therapies</description>
    <arm_group_label>Non-CF bronchiectasis patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>macrolide therapy</intervention_name>
    <description>We will evaluate and compare the clinical effectiveness and safety of long-term inhaled corticosteroid and macrolide antimicrobial therapies</description>
    <arm_group_label>Non-CF bronchiectasis patients</arm_group_label>
    <other_name>azithromycin</other_name>
    <other_name>erythromycin</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients within Medicare with a diagnosis of bronchiectasis
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Within Medicare data, indicated diagnosis of Bronchiectasis by a Pulmonologist (ICD-9
             code 494.0 and/or 494.1)

        Exclusion Criteria:

          -  cystic fibrosis diagnosis, HIV infection, history of organ transplant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kevin L Winthrop, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oregon Health and Science University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Emily Henkle, PhD, MPH</last_name>
    <role>Study Director</role>
    <affiliation>Oregon Health and Science University</affiliation>
  </overall_official>
  <reference>
    <citation>Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992 Jun;45(6):613-9.</citation>
    <PMID>1607900</PMID>
  </reference>
  <reference>
    <citation>Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-83.</citation>
    <PMID>3558716</PMID>
  </reference>
  <results_reference>
    <citation>Henkle E, Curtis JR, Chen L, Chan B, Aksamit TR, Daley CL, Griffith DE, Winthrop KL. Comparative risks of chronic inhaled corticosteroids and macrolides for bronchiectasis. Eur Respir J. 2019 Jul 18;54(1). pii: 1801896. doi: 10.1183/13993003.01896-2018. Print 2019 Jul.</citation>
    <PMID>31000676</PMID>
  </results_reference>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>March 15, 2016</study_first_submitted>
  <study_first_submitted_qc>March 15, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 21, 2016</study_first_posted>
  <results_first_submitted>October 1, 2018</results_first_submitted>
  <results_first_submitted_qc>April 24, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">July 12, 2019</results_first_posted>
  <last_update_submitted>September 4, 2019</last_update_submitted>
  <last_update_submitted_qc>September 4, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oregon Health and Science University</investigator_affiliation>
    <investigator_full_name>Kevin Winthrop</investigator_full_name>
    <investigator_title>Associate Professor, Divisions of Infectious Diseases, and Public Health and Preventive Medicine</investigator_title>
  </responsible_party>
  <keyword>nontuberculous mycobacteria</keyword>
  <keyword>corticosteroids</keyword>
  <keyword>macrolides</keyword>
  <keyword>antibiotics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bronchiectasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azithromycin</mesh_term>
    <mesh_term>Erythromycin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 16, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/83/NCT02714283/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Complete national 2006-2014 Medicare data from Part A, B and D (but not C) were obtained from Center for Medicare and Medicaid Services for patients with ICD-9-CM code 494.0 or 494.1 (bronchiectasis without or with acute exacerbation).</recruitment_details>
      <pre_assignment_details>From the identified bronchiectasis cohort, we excluded patients with cystic fibrosis, HIV infection, or a history of organ transplant. Such patients are fundamentally different than non-CF bronchiectasis patients who lack these factors with regard to their risk for infection, hospitalization, and many of the outcomes under study in this proposal.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Inhaled Corticosteroids (ICS)</title>
          <description>New use was defined as the first prescription for a minimum 28 day (“chronic”) supply of ICS after a clean period of 12 months with no chronic use of either exposure of interest. ICS included ICS alone or in combination with long-acting beta agonists.</description>
        </group>
        <group group_id="P2">
          <title>Macrolide Monotherapy</title>
          <description>New use was defined as the first prescription for a minimum 28 day (“chronic”) supply of macrolide monotherapy after a clean period of 12 months with no chronic use of either exposure of interest. Macrolide monotherapy was defined as oral azithromycin or erythromycin and no other chronic prescription within 30 days that could be associated with NTM therapy (ethambutol, a rifamycin, or a fluoroquinolone). Patients who did not start on macrolide monotherapy were excluded.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="83589"/>
                <participants group_id="P2" count="6500"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="83589"/>
                <participants group_id="P2" count="6500"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Inhaled Corticosteroids (ICS)</title>
          <description>New use was defined as the first prescription for a minimum 28 day (“chronic”) supply of ICS after a clean period of 12 months with no chronic use of either exposure of interest. ICS included ICS alone or in combination with long-acting beta agonists.</description>
        </group>
        <group group_id="B2">
          <title>Macrolide Monotherapy</title>
          <description>New use was defined as the first prescription for a minimum 28 day (“chronic”) supply of macrolide monotherapy after a clean period of 12 months with no chronic use of either exposure of interest. Macrolide monotherapy was defined as oral azithromycin or erythromycin and no other chronic prescription within 30 days that could be associated with NTM therapy (ethambutol, a rifamycin, or a fluoroquinolone). Patients who did not start on macrolide monotherapy were excluded.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="83589"/>
            <count group_id="B2" value="6500"/>
            <count group_id="B3" value="90089"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="83589"/>
                    <measurement group_id="B2" value="6500"/>
                    <measurement group_id="B3" value="90089"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="56583"/>
                    <measurement group_id="B2" value="4750"/>
                    <measurement group_id="B3" value="61333"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27006"/>
                    <measurement group_id="B2" value="1750"/>
                    <measurement group_id="B3" value="28756"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>American Indian or Alaska native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="362"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="379"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian/Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3353"/>
                    <measurement group_id="B2" value="160"/>
                    <measurement group_id="B3" value="3513"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African-American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5338"/>
                    <measurement group_id="B2" value="236"/>
                    <measurement group_id="B3" value="5574"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5188"/>
                    <measurement group_id="B2" value="203"/>
                    <measurement group_id="B3" value="5391"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White (non-Hispanic)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68508"/>
                    <measurement group_id="B2" value="5820"/>
                    <measurement group_id="B3" value="74328"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other/Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="840"/>
                    <measurement group_id="B2" value="64"/>
                    <measurement group_id="B3" value="904"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <title>Midwest</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17129"/>
                    <measurement group_id="B2" value="1612"/>
                    <measurement group_id="B3" value="18741"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Northeast</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18629"/>
                    <measurement group_id="B2" value="992"/>
                    <measurement group_id="B3" value="19621"/>
                  </measurement_list>
                </category>
                <category>
                  <title>South</title>
                  <measurement_list>
                    <measurement group_id="B1" value="33289"/>
                    <measurement group_id="B2" value="2897"/>
                    <measurement group_id="B3" value="36186"/>
                  </measurement_list>
                </category>
                <category>
                  <title>West</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14542"/>
                    <measurement group_id="B2" value="999"/>
                    <measurement group_id="B3" value="15541"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Residential category</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Rural</title>
                  <measurement_list>
                    <measurement group_id="B1" value="65261"/>
                    <measurement group_id="B2" value="4798"/>
                    <measurement group_id="B3" value="70059"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Metropolitan</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18328"/>
                    <measurement group_id="B2" value="1702"/>
                    <measurement group_id="B3" value="20030"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Physician encounters in the 12 month prior to Baseline</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>0-7</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24345"/>
                    <measurement group_id="B2" value="1482"/>
                    <measurement group_id="B3" value="25827"/>
                  </measurement_list>
                </category>
                <category>
                  <title>8-12</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20027"/>
                    <measurement group_id="B2" value="1526"/>
                    <measurement group_id="B3" value="21553"/>
                  </measurement_list>
                </category>
                <category>
                  <title>13-19</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20549"/>
                    <measurement group_id="B2" value="1771"/>
                    <measurement group_id="B3" value="22320"/>
                  </measurement_list>
                </category>
                <category>
                  <title>20+</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18668"/>
                    <measurement group_id="B2" value="1721"/>
                    <measurement group_id="B3" value="20389"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Pulmonologist encounters in the prior 12 months before baseline</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>0</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19013"/>
                    <measurement group_id="B2" value="692"/>
                    <measurement group_id="B3" value="19705"/>
                  </measurement_list>
                </category>
                <category>
                  <title>1</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15157"/>
                    <measurement group_id="B2" value="941"/>
                    <measurement group_id="B3" value="16098"/>
                  </measurement_list>
                </category>
                <category>
                  <title>2</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15437"/>
                    <measurement group_id="B2" value="1032"/>
                    <measurement group_id="B3" value="16469"/>
                  </measurement_list>
                </category>
                <category>
                  <title>3</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11025"/>
                    <measurement group_id="B2" value="1005"/>
                    <measurement group_id="B3" value="12030"/>
                  </measurement_list>
                </category>
                <category>
                  <title>4</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7232"/>
                    <measurement group_id="B2" value="724"/>
                    <measurement group_id="B3" value="7956"/>
                  </measurement_list>
                </category>
                <category>
                  <title>5+</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15725"/>
                    <measurement group_id="B2" value="2106"/>
                    <measurement group_id="B3" value="17831"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Inpatient admissions in the 12 months prior to baseline</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>0</title>
                  <measurement_list>
                    <measurement group_id="B1" value="49795"/>
                    <measurement group_id="B2" value="4108"/>
                    <measurement group_id="B3" value="53903"/>
                  </measurement_list>
                </category>
                <category>
                  <title>1</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17943"/>
                    <measurement group_id="B2" value="1299"/>
                    <measurement group_id="B3" value="19242"/>
                  </measurement_list>
                </category>
                <category>
                  <title>2+</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15851"/>
                    <measurement group_id="B2" value="1093"/>
                    <measurement group_id="B3" value="16944"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hospitalized respiratory infections in the 12 months prior to baseline</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9583"/>
                    <measurement group_id="B2" value="885"/>
                    <measurement group_id="B3" value="10468"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of acute respiratory infections in the 12 months prior to baseline</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>0</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40746"/>
                    <measurement group_id="B2" value="2478"/>
                    <measurement group_id="B3" value="43224"/>
                  </measurement_list>
                </category>
                <category>
                  <title>1</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20193"/>
                    <measurement group_id="B2" value="1384"/>
                    <measurement group_id="B3" value="21577"/>
                  </measurement_list>
                </category>
                <category>
                  <title>2-3</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15993"/>
                    <measurement group_id="B2" value="1499"/>
                    <measurement group_id="B3" value="17492"/>
                  </measurement_list>
                </category>
                <category>
                  <title>4+</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6657"/>
                    <measurement group_id="B2" value="1139"/>
                    <measurement group_id="B3" value="7796"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Comorbidities (any history)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Allergic bronchopulmonary aspergillosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="854"/>
                    <measurement group_id="B2" value="64"/>
                    <measurement group_id="B3" value="918"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alpha-1 antitrypsin deficiency</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="292"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="335"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asthma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33480"/>
                    <measurement group_id="B2" value="1795"/>
                    <measurement group_id="B3" value="35275"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>COPD/emphysema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70548"/>
                    <measurement group_id="B2" value="5050"/>
                    <measurement group_id="B3" value="75598"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interstitial lung disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5526"/>
                    <measurement group_id="B2" value="507"/>
                    <measurement group_id="B3" value="6033"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lung cancer</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3497"/>
                    <measurement group_id="B2" value="196"/>
                    <measurement group_id="B3" value="3693"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NTM History</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3164"/>
                    <measurement group_id="B2" value="1307"/>
                    <measurement group_id="B3" value="4471"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Primary ciliary dyskinesia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="141"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="164"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Primary immune deficiency</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3857"/>
                    <measurement group_id="B2" value="466"/>
                    <measurement group_id="B3" value="4323"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pseudomonas infection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5123"/>
                    <measurement group_id="B2" value="810"/>
                    <measurement group_id="B3" value="5933"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Silicosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="103"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Adapted Charlson comorbidity index (prior 12 months)</title>
          <description>Charlson comorbidity index, higher score is worse.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>0</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20514"/>
                    <measurement group_id="B2" value="1534"/>
                    <measurement group_id="B3" value="22048"/>
                  </measurement_list>
                </category>
                <category>
                  <title>1</title>
                  <measurement_list>
                    <measurement group_id="B1" value="33959"/>
                    <measurement group_id="B2" value="3119"/>
                    <measurement group_id="B3" value="37078"/>
                  </measurement_list>
                </category>
                <category>
                  <title>2+</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29116"/>
                    <measurement group_id="B2" value="1847"/>
                    <measurement group_id="B3" value="30963"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Nontuberculous Mycobacterial (NTM) Disease</title>
        <description>Incidence of treated pulmonary nontuberculous mycobacterium (NTM) disease</description>
        <time_frame>up to 8 years</time_frame>
        <population>Analysis population excluded all patients with a history of NTM treatment or diagnosis prior to exposure start.</population>
        <group_list>
          <group group_id="O1">
            <title>Inhaled Corticosteroids (ICS)</title>
            <description>New use was defined as the first prescription for a minimum 28 day (“chronic”) supply of ICS after a clean period of 12 months with no chronic use of either exposure of interest. ICS included ICS alone or in combination with long-acting beta agonists.</description>
          </group>
          <group group_id="O2">
            <title>Macrolide Monotherapy</title>
            <description>New use was defined as the first prescription for a minimum 28 day (“chronic”) supply of macrolide monotherapy after a clean period of 12 months with no chronic use of either exposure of interest. Macrolide monotherapy was defined as oral azithromycin or erythromycin and no other chronic prescription within 30 days that could be associated with NTM therapy (ethambutol, a rifamycin, or a fluoroquinolone). Patients who did not start on macrolide monotherapy were excluded.</description>
          </group>
        </group_list>
        <measure>
          <title>Nontuberculous Mycobacterial (NTM) Disease</title>
          <description>Incidence of treated pulmonary nontuberculous mycobacterium (NTM) disease</description>
          <population>Analysis population excluded all patients with a history of NTM treatment or diagnosis prior to exposure start.</population>
          <units>Events</units>
          <param>Number</param>
          <units_analyzed>Patient-years</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16136"/>
                <count group_id="O2" value="1496"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Patient-years</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19460"/>
                <count group_id="O2" value="1736"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="188"/>
                    <measurement group_id="O2" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Due to the small sample size in the macrolide monotherapy group, for this outcome, the results are considered exploratory/descriptive only.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.19</p_value>
            <method>Regression, Cox</method>
            <method_desc>Adjusted for propensity score decile, oral corticosteroid use.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.77</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.51</ci_lower_limit>
            <ci_upper_limit>1.14</ci_upper_limit>
            <estimate_desc>ICS (numerator) compared to macrolide monotherapy (denominator)</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Hospitalized Respiratory Infection</title>
        <description>Among a national cohort of non-CF bronchiectasis patients, we will compare the effectiveness of corticosteroid and macrolide therapy with regards to prevention of hospitalized respiratory infection.</description>
        <time_frame>up to 8 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Non-CF Bronchiectasis Patients on ICS Monotherapy</title>
            <description>New use was defined as the first prescription for a minimum 28 day (“chronic”) supply of ICS after a clean period of 12 months with no chronic use of either exposure of interest. ICS included ICS alone or in combination with long-acting beta agonists.</description>
          </group>
          <group group_id="O2">
            <title>Non-CF Bronchiectasis Patients on Macrolide Monotherapy</title>
            <description>New use was defined as the first prescription for a minimum 28 day (“chronic”) supply of macrolide monotherapy after a clean period of 12 months with no chronic use of either exposure of interest. Macrolide monotherapy was defined as oral azithromycin or erythromycin and no other chronic prescription within 30 days that could be associated with NTM therapy (ethambutol, a rifamycin, or a fluoroquinolone). Patients who did not start on macrolide monotherapy were excluded.</description>
          </group>
        </group_list>
        <measure>
          <title>Hospitalized Respiratory Infection</title>
          <description>Among a national cohort of non-CF bronchiectasis patients, we will compare the effectiveness of corticosteroid and macrolide therapy with regards to prevention of hospitalized respiratory infection.</description>
          <units>Events</units>
          <param>Number</param>
          <units_analyzed>Patient-years</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83495"/>
                <count group_id="O2" value="6498"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Patient-years</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33328"/>
                <count group_id="O2" value="3068"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4213"/>
                    <measurement group_id="O2" value="317"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Regression, Cox</method>
            <method_desc>Adjusted for propensity score decile, oral corticosteroid use, and NTM history.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.39</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.23</ci_lower_limit>
            <ci_upper_limit>1.57</ci_upper_limit>
            <estimate_desc>ICS (numerator) compared to macrolide monotherapy (denominator)</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sudden Cardiac Arrest</title>
        <description>Myocardial infarction event</description>
        <time_frame>up to 8 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Non-CF Bronchiectasis Patients on ICS Monotherapy</title>
            <description>New use was defined as the first prescription for a minimum 28 day (“chronic”) supply of ICS after a clean period of 12 months with no chronic use of either exposure of interest. ICS included ICS alone or in combination with long-acting beta agonists.</description>
          </group>
          <group group_id="O2">
            <title>Non-CF Bronchiectasis Patients on Macrolide Monotherapy</title>
            <description>New use was defined as the first prescription for a minimum 28 day (“chronic”) supply of macrolide monotherapy after a clean period of 12 months with no chronic use of either exposure of interest. Macrolide monotherapy was defined as oral azithromycin or erythromycin and no other chronic prescription within 30 days that could be associated with NTM therapy (ethambutol, a rifamycin, or a fluoroquinolone). Patients who did not start on macrolide monotherapy were excluded.</description>
          </group>
        </group_list>
        <measure>
          <title>Sudden Cardiac Arrest</title>
          <description>Myocardial infarction event</description>
          <units>Events</units>
          <param>Number</param>
          <units_analyzed>Patient-years</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83495"/>
                <count group_id="O2" value="6498"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Patient-years</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34688"/>
                <count group_id="O2" value="3171"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="892"/>
                    <measurement group_id="O2" value="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.21</p_value>
            <method>Regression, Cox</method>
            <method_desc>Adjusted for propensity score decile, oral corticosteroid use, and NTM history.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.86</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.67</ci_lower_limit>
            <ci_upper_limit>1.09</ci_upper_limit>
            <estimate_desc>ICS (numerator) compared to macrolide monotherapy (denominator)</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sensorineural Hearing Loss</title>
        <description>Sensorineural hearing loss.</description>
        <time_frame>up to 8 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Non-CF Bronchiectasis Patients on ICS Monotherapy</title>
            <description>Patients prescribed a 28 day or more supply of ICS, with an absence of ICS prescriptions for at least the 12 months prior to identified prescription. ICS include beclomethasone, budesonide, flunisolide, fluticasone, mometasone, triamcinolone, ipratropium/albuterol, budesonide/formoterol, or fluticasone/salmeterol. Exclude baseline 28+ day macrolide, missing geographic or socioeconomic data.</description>
          </group>
          <group group_id="O2">
            <title>Non-CF Bronchiectasis Patients on Macrolide Monotherapy</title>
            <description>Patients prescribed a 28 day or more supply of a macrolide, with an absence of macrolide prescriptions for at least the 12 months prior to identified prescription. Macrolides include oral azithromycin, clarithromycin, and erythromycin. Exclude baseline 28+ day ICS, missing geographic or socioeconomic data</description>
          </group>
        </group_list>
        <measure>
          <title>Sensorineural Hearing Loss</title>
          <description>Sensorineural hearing loss.</description>
          <units>Events</units>
          <param>Number</param>
          <units_analyzed>Patient-years</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83495"/>
                <count group_id="O2" value="6498"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Patient-years</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33491"/>
                <count group_id="O2" value="2993"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2574"/>
                    <measurement group_id="O2" value="347"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Regression, Cox</method>
            <method_desc>Adjusted for propensity score decile, oral corticosteroid use, and NTM history</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.73</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.64</ci_lower_limit>
            <ci_upper_limit>0.82</ci_upper_limit>
            <estimate_desc>ICS (numerator) compared to macrolide monotherapy (denominator)</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hip Fracture</title>
        <description>Hip fracture.</description>
        <time_frame>up to 8 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Non-CF Bronchiectasis Patients on ICS Monotherapy</title>
            <description>New use was defined as the first prescription for a minimum 28 day (“chronic”) supply of ICS after a clean period of 12 months with no chronic use of either exposure of interest. ICS included ICS alone or in combination with long-acting beta agonists.</description>
          </group>
          <group group_id="O2">
            <title>Non-CF Bronchiectasis Patients on Macrolide Monotherapy</title>
            <description>New use was defined as the first prescription for a minimum 28 day (“chronic”) supply of macrolide monotherapy after a clean period of 12 months with no chronic use of either exposure of interest. Macrolide monotherapy was defined as oral azithromycin or erythromycin and no other chronic prescription within 30 days that could be associated with NTM therapy (ethambutol, a rifamycin, or a fluoroquinolone). Patients who did not start on macrolide monotherapy were excluded.</description>
          </group>
        </group_list>
        <measure>
          <title>Hip Fracture</title>
          <description>Hip fracture.</description>
          <units>Events</units>
          <param>Number</param>
          <units_analyzed>Patient-years</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83495"/>
                <count group_id="O2" value="6498"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Patient-years</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34661"/>
                <count group_id="O2" value="3173"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="919"/>
                    <measurement group_id="O2" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.87</p_value>
            <method>Regression, Cox</method>
            <method_desc>Adjusted for propensity score decile, oral corticosteroid use, and NTM history</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.80</ci_lower_limit>
            <ci_upper_limit>1.32</ci_upper_limit>
            <estimate_desc>ICS (numerator) compared to macrolide monotherapy (denominator)</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Opportunistic Infections</title>
        <description>Opportunistic infections.</description>
        <time_frame>up to 8 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Non-CF Bronchiectasis Patients on ICS Monotherapy</title>
            <description>New use was defined as the first prescription for a minimum 28 day (“chronic”) supply of ICS after a clean period of 12 months with no chronic use of either exposure of interest. ICS included ICS alone or in combination with long-acting beta agonists.</description>
          </group>
          <group group_id="O2">
            <title>Non-CF Bronchiectasis Patients on Macrolide Monotherapy</title>
            <description>New use was defined as the first prescription for a minimum 28 day (“chronic”) supply of macrolide monotherapy after a clean period of 12 months with no chronic use of either exposure of interest. Macrolide monotherapy was defined as oral azithromycin or erythromycin and no other chronic prescription within 30 days that could be associated with NTM therapy (ethambutol, a rifamycin, or a fluoroquinolone). Patients who did not start on macrolide monotherapy were excluded.</description>
          </group>
        </group_list>
        <measure>
          <title>Opportunistic Infections</title>
          <description>Opportunistic infections.</description>
          <units>Events</units>
          <param>Number</param>
          <units_analyzed>Patient-years</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83495"/>
                <count group_id="O2" value="6498"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Patient-years</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34200"/>
                <count group_id="O2" value="3113"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1585"/>
                    <measurement group_id="O2" value="180"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.23</p_value>
            <method>Regression, Cox</method>
            <method_desc>Adjusted for propensity score decile, oral corticosteroid use, and NTM history.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.90</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.76</ci_lower_limit>
            <ci_upper_limit>1.07</ci_upper_limit>
            <estimate_desc>ICS (numerator) compared to macrolide monotherapy (denominator)</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All-cause Mortality</title>
        <description>All-cause mortality.</description>
        <time_frame>up to 8 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Non-CF Bronchiectasis Patients on ICS Monotherapy</title>
            <description>New use was defined as the first prescription for a minimum 28 day (“chronic”) supply of ICS after a clean period of 12 months with no chronic use of either exposure of interest. ICS included ICS alone or in combination with long-acting beta agonists.</description>
          </group>
          <group group_id="O2">
            <title>Non-CF Bronchiectasis Patients on Macrolide Monotherapy</title>
            <description>New use was defined as the first prescription for a minimum 28 day (“chronic”) supply of macrolide monotherapy after a clean period of 12 months with no chronic use of either exposure of interest. Macrolide monotherapy was defined as oral azithromycin or erythromycin and no other chronic prescription within 30 days that could be associated with NTM therapy (ethambutol, a rifamycin, or a fluoroquinolone). Patients who did not start on macrolide monotherapy were excluded.</description>
          </group>
        </group_list>
        <measure>
          <title>All-cause Mortality</title>
          <description>All-cause mortality.</description>
          <units>Events</units>
          <param>Number</param>
          <units_analyzed>Patient-years</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83495"/>
                <count group_id="O2" value="6498"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Patient-years</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34912"/>
                <count group_id="O2" value="3193"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3362"/>
                    <measurement group_id="O2" value="270"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.20</p_value>
            <method>Regression, Cox</method>
            <method_desc>Adjusted for propensity score decile, oral corticosteroid use, and NTM history.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.09</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.96</ci_lower_limit>
            <ci_upper_limit>1.25</ci_upper_limit>
            <estimate_desc>ICS (numerator) compared to macrolide monotherapy (denominator)</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All-cause Hospitalization</title>
        <description>All-cause hospitalization.</description>
        <time_frame>up to 8 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Non-CF Bronchiectasis Patients on ICS Monotherapy</title>
            <description>New use was defined as the first prescription for a minimum 28 day (“chronic”) supply of ICS after a clean period of 12 months with no chronic use of either exposure of interest. ICS included ICS alone or in combination with long-acting beta agonists.</description>
          </group>
          <group group_id="O2">
            <title>Non-CF Bronchiectasis Patients on Macrolide Monotherapy</title>
            <description>New use was defined as the first prescription for a minimum 28 day (“chronic”) supply of macrolide monotherapy after a clean period of 12 months with no chronic use of either exposure of interest. Macrolide monotherapy was defined as oral azithromycin or erythromycin and no other chronic prescription within 30 days that could be associated with NTM therapy (ethambutol, a rifamycin, or a fluoroquinolone). Patients who did not start on macrolide monotherapy were excluded.</description>
          </group>
        </group_list>
        <measure>
          <title>All-cause Hospitalization</title>
          <description>All-cause hospitalization.</description>
          <units>Events</units>
          <param>Number</param>
          <units_analyzed>Patient-years</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83495"/>
                <count group_id="O2" value="6498"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Patient-years</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28882"/>
                <count group_id="O2" value="2729"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17939"/>
                    <measurement group_id="O2" value="1352"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Regression, Cox</method>
            <method_desc>Adjusted for propensity score decile, oral corticosteroid use, and NTM history</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.15</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.08</ci_lower_limit>
            <ci_upper_limit>1.21</ci_upper_limit>
            <estimate_desc>ICS (numerator) compared to macrolide monotherapy (denominator)</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hemoptysis</title>
        <description>Hemoptysis event</description>
        <time_frame>up to 8 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Non-CF Bronchiectasis Patients on ICS Monotherapy</title>
            <description>New use was defined as the first prescription for a minimum 28 day (“chronic”) supply of ICS after a clean period of 12 months with no chronic use of either exposure of interest. ICS included ICS alone or in combination with long-acting beta agonists.</description>
          </group>
          <group group_id="O2">
            <title>Non-CF Bronchiectasis Patients on Macrolide Monotherapy</title>
            <description>New use was defined as the first prescription for a minimum 28 day (“chronic”) supply of macrolide monotherapy after a clean period of 12 months with no chronic use of either exposure of interest. Macrolide monotherapy was defined as oral azithromycin or erythromycin and no other chronic prescription within 30 days that could be associated with NTM therapy (ethambutol, a rifamycin, or a fluoroquinolone). Patients who did not start on macrolide monotherapy were excluded.</description>
          </group>
        </group_list>
        <measure>
          <title>Hemoptysis</title>
          <description>Hemoptysis event</description>
          <units>Events</units>
          <param>Number</param>
          <units_analyzed>Patient-years</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83495"/>
                <count group_id="O2" value="6498"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Patient-years</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34835"/>
                <count group_id="O2" value="3185"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="253"/>
                    <measurement group_id="O2" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.99</p_value>
            <method>Regression, Cox</method>
            <method_desc>Adjusted for propensity score decile, oral corticosteroid use, and NTM history</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.66</ci_lower_limit>
            <ci_upper_limit>1.51</ci_upper_limit>
            <estimate_desc>ICS (numerator) compared to macrolide monotherapy (denominator)</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Arrhythmia</title>
        <description>Arrhythmia (principal diagnosis)</description>
        <time_frame>up to 8 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Non-CF Bronchiectasis Patients on ICS Monotherapy</title>
            <description>New use was defined as the first prescription for a minimum 28 day (“chronic”) supply of ICS after a clean period of 12 months with no chronic use of either exposure of interest. ICS included ICS alone or in combination with long-acting beta agonists.</description>
          </group>
          <group group_id="O2">
            <title>Non-CF Bronchiectasis Patients on Macrolide Monotherapy</title>
            <description>New use was defined as the first prescription for a minimum 28 day (“chronic”) supply of macrolide monotherapy after a clean period of 12 months with no chronic use of either exposure of interest. Macrolide monotherapy was defined as oral azithromycin or erythromycin and no other chronic prescription within 30 days that could be associated with NTM therapy (ethambutol, a rifamycin, or a fluoroquinolone). Patients who did not start on macrolide monotherapy were excluded.</description>
          </group>
        </group_list>
        <measure>
          <title>Arrhythmia</title>
          <description>Arrhythmia (principal diagnosis)</description>
          <units>events</units>
          <param>Number</param>
          <units_analyzed>person-years</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83495"/>
                <count group_id="O2" value="6498"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>person-years</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31395"/>
                <count group_id="O2" value="2855"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9508"/>
                    <measurement group_id="O2" value="728"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0005</p_value>
            <method>Regression, Cox</method>
            <method_desc>Adjusted for propensity score decile, oral corticosteroid use, and NTM history</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.15</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.07</ci_lower_limit>
            <ci_upper_limit>1.25</ci_upper_limit>
            <estimate_desc>ICS (numerator) compared to macrolide monotherapy (denominator)</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>This is a retrospective observational study. Only medical history data was collected.</time_frame>
      <desc>All-Cause Mortality, Serious, and Other Adverse Events were not monitored. We report Safety Outcomes in the Outcomes section.</desc>
      <group_list>
        <group group_id="E1">
          <title>Non-CF Bronchiectasis Patients on ICS Monotherapy</title>
          <description>Patients prescribed a 28 day or more supply of ICS, with an absence of ICS prescriptions for at least the 12 months prior to identified prescription. ICS include beclomethasone, budesonide, flunisolide, fluticasone, mometasone, triamcinolone, ipratropium/albuterol, budesonide/formoterol, or fluticasone/salmeterol. Exclude baseline 28+ day macrolide, missing geographic or socioeconomic data.</description>
        </group>
        <group group_id="E2">
          <title>Non-CF Bronchiectasis Patients on Macrolide Monotherapy</title>
          <description>Patients prescribed a 28 day or more supply of a macrolide, with an absence of macrolide prescriptions for at least the 12 months prior to identified prescription. Macrolides include oral azithromycin, clarithromycin, and erythromycin. Exclude baseline 28+ day ICS, missing geographic or socioeconomic data</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Claims-based data limits our ability to confirm bronchiectasis diagnoses and include disease symptoms/severity in our models. Results may not be applicable to &lt;65 year old bronchiectasis patients who have a lower underlying risk of pneumonia.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Emily Henkle, PhD, MPH</name_or_title>
      <organization>Oregon Health &amp; Science University</organization>
      <phone>503-494-6226</phone>
      <email>henkle@ohsu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

